Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $22.80.

ZVRA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research note on Tuesday, December 30th. Cantor Fitzgerald cut their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th.

Insider Activity at Zevra Therapeutics

In related news, SVP Timothy J. Sangiovanni sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the sale, the senior vice president owned 29,590 shares of the company’s stock, valued at $271,636.20. This trade represents a 9.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Adrian W. Quartel sold 4,533 shares of the company’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total value of $40,026.39. Following the transaction, the insider directly owned 9,723 shares in the company, valued at $85,854.09. This trade represents a 31.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 114,158 shares of company stock worth $1,062,878. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC boosted its holdings in Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after purchasing an additional 2,297 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after buying an additional 1,280 shares during the period. Russell Investments Group Ltd. raised its holdings in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares in the last quarter. Finally, Creative Planning acquired a new position in shares of Zevra Therapeutics in the 2nd quarter valued at approximately $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.97 on Wednesday. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The firm has a market cap of $504.99 million, a P/E ratio of 19.09 and a beta of 0.99. The stock has a fifty day moving average price of $8.72 and a two-hundred day moving average price of $9.12. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.